ZUELLIG PHARMA OVERSEAS (MM) PTE. LTD.

Business Description

ZUELLIG PHARMA OVERSEAS (MM) PTE. LTD. is registered as a business entity on 03 May 2017 (7.8 years ago) structured as a Private Company Limited By Shares (Local Company) with 4 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 201712166R. The business official address is located at 47 Scotts Road #10-00, Goldbell Towers, Singapore 228233 with main trading activity as Distribution And Marketing Of Pharmaceutical Products. in the primary industry of 46461: Wholesale Of Medicinal And Pharmaceutical Products (western) using Singapore Dollars - SGD as its default trading currency. The business name remains unchanged since inception. The business annual account filing date falls on 31 July and is currently operational with the status of 'Live Company'. The business paid up share capital is SGD 30,000, with preference share capital of SGD 0, and other share capital at SGD 0.

In the past 365 days, ZUELLIG PHARMA OVERSEAS (MM) PTE. LTD. has received a total of Login to view reported payment review(s). 9 were rated Good and Login to view were rated Poor. The latest review was made on 2023-09-29 and it was reported "Good". The aggregated good payment amount is equivalent to USD 2,826, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The appointment of KPMG LLP as auditor indicates that the business is medium to large sized as it is required to meet additional regulatory requirements either due to reported revenue or assets exceeding SGD 10 million or has more than 50 employees in the previous two fiscal years.

ZUELLIG PHARMA OVERSEAS (MM) PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023